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Abstract
Introduction: Atypical	polypoid	adenomyoma	is	an	uncommon	uterine	lesion	which	
can	coexist	with	endometrial	atypical	hyperplasia	and/or	cancer.	Atypical	polypoid	
adenomyoma	affects	premenopausal	women	in	most	cases,	but	it	shows	high	recur‐
rence	rate	if	conservatively	treated.	To	date,	the	management	of	patients	is	based	on	
low‐quality	evidence	and	 is	not	standardized.	Our	primary	aim	was	to	explore	 the	
optimal	management	of	atypical	polypoid	adenomyoma,	with	particular	regard	to	the	
fertility‐sparing	approach.	The	 secondary	aim	was	 to	define	 clinicopathologic	 fea‐
tures	of	atypical	polypoid	adenomyoma.
Material and methods: Medline,	Embase,	Web	of	Sciences,	Scopus,	ClinicalTrial.gov,	
OVID,	Google	Scholar	and	Cochrane	Library	were	searched	for	studies	reporting	out‐
comes	of	atypical	polypoid	adenomyoma	treatments.	Univariate	comparisons	among	
outcomes	of	fertility‐sparing	treatments	(rates	of	initial	response,	progression,	recur‐
rence,	final	complete	response,	pregnancy)	were	performed	with	Fisher's	exact	test	
(α	=	.05).
Results: Eleven	retrospective	studies	with	237	patients	were	included;	85.5%	of	pa‐
tients	were	premenopausal	and	62.9%	were	nulliparous.	Atypical	polypoid	adenom‐
yoma	 coexisted	 with	 atypical	 hyperplasia	 in	 5.5%	 of	 cases	 and	 with	 endometrial	
cancer	in	5.9%.	Overall	risks	of	recurrence	and	progression	to	cancer	were	28.9%	and	
16.6%,	respectively.	Fertility‐sparing	treatments	included	hormonal	therapy	with	or	
without	maintenance,	hysteroscopic	transcervical	resection,	dilation	and	curettage,	
and	hormonal	therapy	combined	with	transcervical	resection	or	dilation	and	curet‐
tage.	 Transcervical	 resection	 showed	 significantly	 higher	 initial	 response	 rates	 (P 
from	<.001	to	.023)	than	any	other	treatment.	Transcervical	resection	and	transcervi‐
cal	 resection+hormonal	 therapy	 showed	 significantly	 lower	 progression	 rates	
(P < .001),	and	higher	final	complete	response	rates	(P < .001)	than	any	other	treat‐
ment.	No	significant	differences	were	found	in	the	rates	of	pregnancy	(P = .533‐.647)	
or	 recurrence	 (P = .052‐.475).	 Among	 the	 different	 transcervical	 resection	 tech‐
niques,	 the	 4‐step	 transcervical	 resection	 showed	 significantly	 lower	 rates	 of	
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1  | INTRODUC TION
Atypical	 polypoid	 adenomyoma	 or	 atypical	 polypoid	 adenomy‐
ofibroma	of	 the	uterus	 (APA)	 is	 an	uncommon	uterine	 lesion,	 first	
described	by	Mazur	in	1981.1	Histologically,	it	is	a	biphasic	prolifera‐
tion,	which	consists	of	atypical	endometrial	glands	with	squamous	
morular	differentiation	in	a	background	of	profuse	myofibromatous	
stroma.2	Its	histological	pattern	mimics	adenocarcinoma	infiltrating	
myometrium,	or	malignant	mixed	mullerian	tumor.1
Although	APA	is	considered	as	a	benign	tumor,	it	can	coexist	with	
endometrial	 atypical	 hyperplasia	 and/or	 endometrioid	 adenocarci‐
noma.3	Moreover,	APA	shows	high	 recurrence	 rates	when	conser‐
vatively treated.3,4	Therefore,	hysterectomy	has	been	considered	as	
the	treatment	of	choice	for	this	lesion.4
However,	 since	 APA	 affects	 premenopausal	 women	 in	 most	
cases,5‐7	 a	 fertility‐sparing	 approach	 appears	 necessary.	 Several	
conservative	 treatments	 have	 been	 adopted,	 including	 progestin‐
based	 hormonal	 therapy	 (HT)	 with	 or	 without	 maintenance	 (M),	
hysteroscopic	 transcervical	 resection	 (TCR),	dilation	and	curettage	
(D&C)	or	the	combination	of	HT	with	TCR	or	D&C.1,5‐14
Given	 the	 rarity	 of	 APA,	 no	 prospective	 trials	 have	 been	 per‐
formed,	and	the	management	of	patients	has	never	been	standard‐
ized.	As	a	result,	there	is	no	consensus	on	the	optimal	treatment	and	
follow	up	of	APA.
In	fact,	several	clinicopathologic	features	of	APA,	such	as	charac‐
teristics	of	the	patients,	symptoms,	associations	with	other	diseases,	
localization	 in	 the	uterus,	actual	 risk	of	 recurrence,	malignant	pro‐
gression	and	coexistence	with	endometrial	atypical	hyperplasia	and/
or	cancer,	are	not	well‐defined.
The	objective	of	this	quantitative	systematic	review	was	to	pro‐
vide	a	comprehensive	and	updated	overview	about	all	aspects	of	this	
rare	 uterine	 lesion.	 In	 particular,	 our	 primary	 aim	was	 to	 compare	
effectiveness	and	safety	of	the	several	conservative	treatments	de‐
scribed	in	the	literature.	We	aimed	to	provide	statistical	evidence	to	
support	the	standardization	of	the	patient	management.
2  | MATERIAL AND METHODS
This	study	was	performed	following	a	protocol	recommended	for	sys‐
tematic	review.	The	protocol	defining	methods	for	collecting,	extract‐
ing	and	analyzing	data	was	designed	a	priori.	All	steps	were	conducted	
independently	by	two	reviewers	(A.R.,	A.T.).	These	two	authors	inde‐
pendently	performed	electronic	search,	evaluation	of	eligibility	of	the	
studies,	 risks	 of	 bias	 assessment,	 data	 extraction	 and	 data	 analysis.	
Disagreements	were	resolved	by	discussion	with	a	third	reviewer	(G.S.).
The	study	was	reported	according	to	the	Preferred	Reporting	Item	
for	Systematic	Reviews	and	Meta‐analyses	(PRISMA)	statement.15
2.1 | Search strategy
Several	 researches	were	performed	using	MEDLINE,	Embase,	Web	
of	 Sciences,	 Scopus,	 ClinicalTrial.gov,	 OVID,	 Google	 Scholar	 and	
Cochrane	Library	as	electronic	databases.	The	relevant	articles	were	
searched	 from	 the	 inception	 to	May	 2018	 using	 a	 combination	 of	
the	 following	 text	words	 and	 all	 their	 synonyms	 found	on	Medical	
SubHeading	 (MeSH)	 vocabulary:	 “atypical	 polypoid	 adenomyoma”;	
“APA”;	 “adenofibroma”;	 “adenomyofibroma”;	 “uterus”;	 “uterine”;	
“endometrial”;	 “myometrium”;	 “treatment”;	 “fertility‐sparing”;	 “con‐
servative”;	 “MPA”;	 “medroxyprogesterone”;	 “LNG‐IUD”;	 “Mirena”;	
“levonorgestrel”;	 “progesterone”;	 “progestogen”;	 “progestin”;	
progression	(P = .002)	and	recurrence	(P = .013)	than	other	techniques.	Limitations	to	
our	results	were	the	retrospective	design	of	the	studies	and	the	relatively	small	sam‐
ple	size,	due	to	the	rarity	of	atypical	polypoid	adenomyoma.
Conclusions: Based	on	 its	effectiveness	and	safety,	 transcervical	 resection	may	be	
the	 first‐line	 fertility‐sparing	 treatment	 for	 atypical	 polypoid	 adenomyoma.	 In	 par‐
ticular,	4‐step	transcervical	resection	showed	the	best	results.	Given	the	risk	of	recur‐
rence,	progression	and	coexistent	atypical	hyperplasia	or	cancer,	follow‐up	biopsies	
are	 advisable.	When	 fertility	 preservation	 is	 not	 required,	 hysterectomy	might	 be	
advisable.
K E Y W O R D S
atypical	polypoid	adenomyofibroma,	conservative	treatment,	endometrium,	hysteroscopy,	
progestin,	transcervical	resection
Key message
Transcervical	 resection	 should	 be	 the	 first‐line	 fertility‐
sparing	 treatment	 for	 atypical	 polypoid	 adenomyoma.	 In	
particular,	the	4‐step	resection	technique	might	be	an	op‐
timal	approach.	Follow‐up	biopsies	appear	necessary,	and	
hysterectomy	might	be	advisable	when	fertility	preserva‐
tion	is	not	required.
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“response”;	 “resistance”;	 “persistence”;	 “relapse”;	 “recurrence”;	 “pro‐
gression”;	“outcome”;	“precancerous”;	“premalignant”;	“precursor”.	In	
addition,	reference	lists	of	relevant	studies	were	reviewed.
2.2 | Study selection
All	peer‐reviewed,	prospective	or	retrospective	studies	reporting	a	
series	of	patients	with	APA	who	underwent	any	type	of	treatment	
were	included	in	the	systematic	review.
Exclusion	criteria	were:
•	 studies	not	reporting	the	treatment;
•	 studies	not	reporting	outcomes	of	treatment;
•	 case	reports	and	reviews.
2.3 | Data extraction
Data	from	each	eligible	study	were	extracted	without	modification	
of	original	data	according	to	PICOS.
Population	(P)	of	our	study	was	constituted	of	women	diagnosed	
with	APA.
Interventions	 (I)	 included	 all	 treatments	 performed	 for	 APA.	
Treatments	of	APA	were	subdivided	into	conservative	and	non‐con‐
servative.	Conservative	treatments	included	TCR,	HT,	HT+M,	D&C,	
vaginal	 resection,	or	a	combination	of	TCR	or	D&C	with	HT.	Non‐
conservative	treatments	included	simple	hysterectomy	or	hysterec‐
tomy	plus	bilateral	salpingo‐oophorectomy	(HBSO).
Comparisons	 (C)	 were	 performed	 among	 conservative	 treat‐
ments	(see	data	analysis).
Outcomes	 (O)	of	 the	conservative	 treatments	were	subdivided	
into	oncologic	and	reproductive	outcomes.
Oncologic	outcomes	considered	were	the	following:
•	 initial	response,	defined	as	regression	of	APA	on	histological	ex‐
amination	at	6	months‐follow	up;
•	 recurrence,	defined	as	a	new	finding	of	APA	on	follow‐up	biopsy	
after	a	complete	regression;	multiple	recurrences	were	consecu‐
tively numbered;
•	 final	complete	response,	defined	as	complete	regression	of	APA	at	
the	end	of	the	follow‐up	period;
•	 progression,	defined	as	progression	of	APA	to	endometrial	endo‐
metrioid adenocarcinoma;
•	 disease‐free	 interval,	defined	as	the	time	between	complete	re‐
sponse	and	recurrence.
Additional	oncologic	outcomes	were:
•	 persistence,	defined	as	the	presence	of	APA	on	histological	exam‐
ination	at	6	months‐follow	up;
•	 final	hysterectomy,	defined	as	hysterectomy	after	a	failed	conser‐
vative	treatment	(due	to	progression	to	cancer	or	association	with	
endometrial	atypical	hyperplasia);
•	 time	to	hysterectomy,	defined	as	the	time	in	months	between	the	
beginning	of	the	conservative	treatment	and	hysterectomy	after	
the	failure	of	treatment.
Reproductive	outcomes	were	defined	as	pregnancies	after	a	con‐
servative	approach.
Study	design	(S)	was	retrospective	case	series	(the	only	possible	
design	given	the	rarity	of	APA).
2.4 | Risk of bias assessment
The	risk	of	bias	was	assessed	via	the	Methodological	Index	for	Non‐
Randomized	Studies	 (MINORS).16	Seven	domains	 related	to	risk	of	
bias	were	evaluated	in	each	study:	(1)	aim	(ie,	clearly	stated	aim);	(2)	
inclusion	of	consecutive	patients	(ie,	all	patients	satisfying	the	crite‐
ria	for	inclusion	were	included	in	the	study	during	the	study	period);	
(3)	prospective	collection	of	data	(ie,	data	were	collected	according	
to	a	protocol	established	before	the	beginning	of	the	study);	(4)	end‐
points	appropriate	 to	 the	aim	 (ie,	unambiguous	explanation	of	 the	
criteria	used	to	measure	outcomes);	(5)	unbiased	assessment	of	the	
study	endpoint	(ie,	the	study	endpoint	was	assessed	without	bias);	
(6)	 follow‐up	 period	 appropriate	 to	 the	 aim	 (ie,	 the	 follow	up	was	
sufficiently	long	to	allow	the	assessment	of	the	main	endpoint),	(7)	
loss	to	follow	up	less	than	5%	(ie,	no	more	than	5%	of	patients	were	
lost	 to	 follow	up).	Review	authors’	 judgments	were	categorized	as	
“low	risk”,	 “unclear	 risk”	or	 “high	risk”	of	bias	 if	data	 regarding	 the	
domain	were	“reported	and	adequate”,	“reported	but	inadequate”	or	
“not	reported”,	respectively.
2.5 | Data analysis
Univariate	comparisons	among	conservative	treatments	and	among	
different	TCR	techniques	were	performed	using	Fisher's	exact	test	
for	a	two‐tailed	P‐value	with	α	=	.05	significance	level	for	each	onco‐
logic	or	reproductive	outcome.	Meta‐analysis	was	not	feasible	due	
to	the	absence	of	comparison	among	the	conservative	approaches	
in	the	individual	studies.
Studies	with	overlapping	data	were	considered	as	one	study	 in	
the	data	analysis.
The	 data	 analysis	 was	 performed	 using	 Review ManageR 5.3 
(Copenhagen:	The	Nordic	Cochrane	Centre,	Cochrane	Collaboration,	
2014).
3  | RESULTS
3.1 | Study selection
In	all,	333	studies	were	identified	through	database	searching.	103	ar‐
ticles	remained	after	duplicate	removal,	of	which	90	were	considered	
relevant	and	were	screened.	Thirteen	studies	were	assessed	for	eligi‐
bility;	after	applying	exclusion	criteria,	two	of	them	were	excluded.	The	
last	11	retrospective	studies	with	a	total	of	237	APA	were	included	in	
the	quantitative	systematic	review.1,5‐14	Two	of	the	included	studies8,9 
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reported	overlapping	data	and	were	considered	as	one	study	 in	the	
data analysis.
Details	about	the	whole	process	of	study	selection	are	reported	
in	Supporting	Information	Figure	S1.
3.2 | Risk of bias assessment
Results	 of	 risk	 of	 bias	 assessment	 are	 shown	 in	 Supporting	
Information	Figure	S2.
For	the	“aim”,	“inclusion	of	consecutive	patients”	and	“prospec‐
tive	collection	of	data”	domains,	all	the	included	studies	were	classi‐
fied	as	low	risk	of	bias,	since	they	had	a	clearly	stated	aim,	included	
consecutively	all	eligible	patients,	and	collected	data	according	to	a	
previously	defined	protocol,	respectively.
For	the	“endpoints	appropriate	to	the	aim”	domain,	three	stud‐
ies5,10,14	were	classified	as	unclear	risk	of	bias	because	they	did	not	
assess	 reproductive	 outcomes,	 ans	 one11	 was	 categorized	 as	 high	
risk	since	it	assessed	recurrence	as	the	only	outcome	of	treatment.	
Other	studies	were	as	low	risk	of	bias	because	they	evaluated	both	
oncologic	and	reproductive	outcomes.
For	 the	 “unbiased	 assessment	 of	 the	 study	 endpoint”	 do‐
main,	five	studies	were	categorized	as	low	risk	of	bias	since	they	
performed	histological	examination	at	every	 follow‐up	visit.5,8‐
10,13	Six	studies	were	classified	as	unclear	risk	because	they	per‐
formed	 histological	 examination	 only	 when	 ultrasonographic	
findings	 were	 suspicious,	 or	 if	 they	 did	 not	 specify	 whether	
histological	 examination	 was	 performed	 at	 every	 follow‐up	
visit.1,6,7,11,12,14
For	the	“follow‐up	period	appropriate	to	the	aim”	domain,	all	the	
included	studies	were	classified	as	low	risk	of	bias	because	the	fol‐
low‐up	period	they	considered	was	long	enough	to	assess	the	main	
endpoints.
For	the	“loss	to	follow	up	 less	<5%”	domain,	nine	studies	were	
categorized	as	 low	risk	of	bias,	whereas	two	were	classified	as	un‐
clear	risk	because	more	than	5%	of	patients	(18.5%	and	5.7%)5,7
3.3 | Characteristics of patients
Patient	age	ranged	between	17	and	73	years;	body	mass	index	(BMI)	was	
between	 16.6	 and	 28.7	kg/m2;	 85.5%	 of	women	were	 premenopausal	
and	62.9%	were	nulliparous;	35.4%	had	menstrual	cycle	irregularity	and	
18.6%	were	infertile.	The	most	common	symptoms	were:	abnormal	uter‐
ine	bleeding	 (28%),	menorrhagia	 (19.8%),	 hypermenorrhea	 (18.7%),	 dys‐
menorrhea	(4.9%),	metrorrhagia	(3.8%),	secondary	anemia	(2.2%),	vaginal	
discharge	(1.1%),	mass	in	the	uterine	cavity	(1.1%),	vaginal	bleeding	(.5%),	
menostaxis	(.5%)	and	amenorrhea	(.5%).	Only	2.2%	were	asymptomatic.	
Uterine	leiomyoma	was	the	most	commonly	associated	pathology	(10.9%).
Details	about	characteristics	of	patients	are	reported	in	Table	1.
3.4 | Characteristics of APA
APA	was	 diagnosed	 in	 59.4%	 on	 histological	 examination	 of	 D&C	
specimen,	32.1%	on	hysteroscopic	biopsies,	5.5%	on	hysterectomy	
for	other	 indications,	1.8%	on	cervical	polypectomy	specimen	and	
1.2%	on	HBSO	for	other	indications.
Atypical	polypoid	adenomyoma	localization	was	uterine	fundus	
in	55.8%	of	cases,	lower	segment	of	the	uterus	in	32.7%	and	uterine	
cervix	 in	11.5%.	APA	diameter	 ranged	between	1	and	70	mm;	 the	
weight	of	 the	 resected	 lesion	was	 reported	only	 in	one	study	and	
ranged	between	.5	and	25	g	with	a	mean	of	4	g.7
On	histological	examination,	the	most	common	pathologies	as‐
sociated	with	APA	were:	adenomyosis	(20.7%),	endometrial	cancer	
(5.9%),	atypical	endometrial	hyperplasia	 (5.5%),	endometrial	hyper‐
plasia	without	atypia	(3.8%)	and	ovarian	cancer	(2.1%).
Characteristics	of	APA	are	reported	in	detail	in	Table	2.
3.5 | Non‐conservative treatments
A	 total	 of	 58	 patients	were	 non‐conservatively	 treated.	 Fourteen	
(24.1%)	women	underwent	simple	hysterectomy	(in	9	cases	for	other	
indications),	7	(12%)	HBSO	(in	2	cases	for	other	indications),	3	(5.2%)	
primary	cytoreductive	surgery,	1	(1.7%)	chemotherapy	for	coexisting	
cancer,	1	(1.7%)	hysterectomy	+	radiotherapy	for	misinterpretation	
as	a	carcinoma,	1	(1.7%)	HBSO	+	radiotherapy	for	misinterpretation	
as	a	carcinoma,	and	1	(1.7%)	hysterectomy	+	chemotherapy	for	mis‐
interpretation	as	a	carcinosarcoma.
3.6 | Conservative treatments
A	 total	 of	 169	 patients	 were	 conservatively	 treated:	 91	 (53.8%)	
women	 underwent	 TCR,	 39	 (23.1%)	 TCR+HT,	 18	 (10.7%)	 HT	 (of	
whom	5	with	M),	17	(10.1%)	D&C,	2	(1.2%)	D&C+HT,	and	2	(1.2%)	
vaginal	 resection.	 Three	 studies	 described	 in	 detail	 on	 the	 TCR	
technique	adopted.7,12,14	TCR	techniques	were:	4‐step	TCR	accord‐
ing	to	Di	Spiezio	Sardo	et	al	in	the	study	by	Ma	et	al,14step	TCR	+	in‐
trauterine	device	insertion	(to	prevent	adherences)	in	the	study	by	
Chiyoda	et	al,7	and	TCR	+	curettage	in	the	study	by	Grimbizis	et	al.12
3.7 | Follow‐up of conservative approach
In	three	studies,	the	follow	up	of	patients	conservatively	treated	was	
based	on	D&C	or	hysteroscopic	biopsy	and	transvaginal	ultrasonog‐
raphy	every	3‐6	months.8,9,13	 In	 three	other	studies,	hysteroscopic	
biopsy	were	performed	only	when	ultrasonographic	 findings	were	
suspicious.7,12,14	 In	 two	 studies	 the	 follow	 up	 was	 based	 on	 D&C	
without	specifying	the	interval	between	each	D&C.5,10	Three	stud‐
ies 1,6,11	did	not	report	details	about	follow	up.	The	follow‐up	time	
ranged	 between	 1	 and	 276	months.	 CA125	 and	 CA19.9	 were	 as‐
sessed	in	only	one	study,	showing	normal	values.7
Details	about	treatments	and	follow	up	are	shown	in	Table	3.
3.8 | Oncologic outcomes of 
conservative treatments
Combining	all	conservative	treatments,	initial	response	occurred	in	
86%	of	patients,	progression	 in	16.6%,	recurrence	 in	28.9%	with	a	
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disease‐free	 interval	 ranging	 between	 1	 and	 60	months,	 and	 final	
complete	response	in	69.9%.	No	death	from	APA	was	reported.
Initial	response	was	significantly	more	common	in	TCR	(98.7%)	
than	HT	(77.7%;	P = .004),	TCR+HT	(69.2%;	P < .001)	or	D&C	(75%;	
P = .023).
The	 rate	 of	 progression	 to	 cancer	 did	 not	 significantly	 differ	
between	 TCR	 (10.8%)	 and	 TCR+HT	 (5.1%;	 P = .49),	 but	 TCR	 and	
TCR+HT	showed	significantly	fewer	progressions	than	HT	without	
M	(69.2%;	P < .001).
No	 significant	 differences	 in	 the	 recurrence	 rates	 were	 found	
between	TCR+HT	 (17.9%)	 and	TCR	 (29.8%;	P = .191),	D&C	 (36.4%;	
P = .475)	or	HT	without	M	(44.4%;	P = .052).
Concerning	 final	 complete	 response	 rates,	 no	 significant	 dif‐
ferences	 were	 found	 between	 TCR	 (77.3%)	 and	 TCR+HT	 (82.1%;	
P = .634),	 but	 both	 approaches	 showed	 significantly	 higher	 rates	
than	HT	without	M	(15.4%;	P < .001).
Due	to	 the	 low	number	of	patients,	D&C	and	HT+M	could	not	
be	 compared	 with	 other	 conservative	 approaches	 regarding	 final	
complete	response,	final	hysterectomy	or	progression.	For	the	same	
reason,	oncologic	outcomes	of	D&C+HT	could	not	be	compared	with	
those	of	other	treatments.
Results	on	oncologic	outcomes	of	the	several	treatments	are	re‐
ported	 in	detail	 in	Table	4;	details	about	 recurrent	APA	are	shown	
in	Table	S1;	additional	oncologic	outcomes	are	reported	in	Table	4.
3.9 | Reproductive outcomes of 
conservative treatments
Pregnancy	was	 achieved	 in	 25.3%	 of	 all	 patients	 who	 underwent	
conservative	treatment.	No	significant	differences	in	the	pregnancy	
rates	were	found	between	HT	with	M	 (40%)	and	TCR+HT	 (30.8%;	
P = .647),	TCR	(21.1%;	P = .575),	HT	without	M	(15.4%;	P = .533).
Reproductive	outcomes	were	not	reported	for	D&C	and	D&C+HT.	
Two	studies	also	reported	pregnancies	after	recurrence.6,7	Two	pa‐
tients	conceived	two	times	after	treatment	with	HT	or	TCR+HT.8,13
Reproductive	outcomes	are	detailed	in	Table	5.
3.10 | Comparison among TCR techniques
The	 4‐step	 technique	 showed	 the	 best	 results	 (100%	 initial	 response,	
83.3%	final	complete	response,	10%	recurrence,	0%	progression).14	The	
4‐step	TCR	showed	significantly	lower	progression	and	recurrence	rates	
than	1‐step	TCR+	intrauterine	device7	(P = .002 and P = .013,	respectively).	
No	significant	differences	were	found	between	4‐step	TCR	and	TCR	+	cu‐
rettage.12	No	significant	differences	were	found	for	any	other	outcomes.
Details	about	outcomes	of	different	TCR	techniques	are	shown	
in	Table	6.
4  | DISCUSSION
We	found	that	TCR	obtained	a	significantly	higher	 initial	 response	
rate	 than	 any	 other	 conservative	 treatment.	 TCR	 and	 TCR+HT	
showed	 higher	 final	 complete	 response	 rate	 and	 lower	 progres‐
sion	rate	than	HT	without	M.	No	significant	differences	were	found	
among	 the	 several	 conservative	 approaches	 regarding	 recurrence	
and	pregnancy	 rates.	Among	 the	different	TCR	 techniques,	 the	4‐
step	TCR	performed	in	the	study	by	Ma	et	al14	showed	the	best	out‐
comes.	The	risk	of	recurrence	(29.8%)	and	progression	(10.8%)	was	
high	even	after	TCR.
Many	case	reports	of	APA	were	published	in	the	literature,	but	
only	a	few	large	patient	series	were	available.	Therefore,	clinicopath‐
ologic	characteristics	of	APA	are	not	well‐defined.
Despite	a	wide	age	range	(17‐73),	we	found	that	most	women	
were	 premenopausal	 (85%)	 and	 nulliparous	 (62.9%),	 empha‐
sizing	 the	 importance	 of	 an	 effective	 and	 safe	 fertility‐sparing	
treatment.	Regarding	symptom	presentation,	APA	was	rarely	an	
incidental	 finding.	 Amenorrhea	 was	 present	 in	 only	 one	 case,7 
whereas	most	patients	showed	abnormal	uterine	bleeding	(28%).	
For	this	reason,	most	APA	was	diagnosed	on	histological	examina‐
tion	of	D&C	(59.4%)	or	hysteroscopic	specimen	(32.1%).	APA	was	
more	commonly	localized	in	the	uterine	fundus	(55.8%),	contrary	
to	what	was	previously	reported	(lower	uterine	segment)4;	how‐
ever,	 it	 should	 be	 underlined	 that	 we	 included	 only	 studies	 re‐
porting	outcomes	of	treatment,	and	some	studies	did	not	report	
localization	(Table	2).
It	appears	crucial	to	quantify	the	actual	risk	of	coexistent	endo‐
metrial	atypical	hyperplasia	or	endometrioid	adenocarcinoma	when	
a	conservative	approach	is	considered.	According	to	the	2014	WHO	
classification,	 atypical	 hyperplasia	 (endometrioid	 intraepithelial	
neoplasia)	is	the	precursor	of	endometrioid	adenocarcinoma	and	is	
differentiated	 from	hyperplasia	without	atypia	 (a	benign	prolifera‐
tion)	based	on	the	presence	of	cytological	atypia.17	We	found	that	
APA	was	associated	with	atypical	hyperplasia	in	5.5%	of	the	patients	
and	with	endometrial	cancer	in	5.9%.	These	risks	appear	lower	than	
those	previously	reported	in	the	literature	(8.8%	for	atypical	hyper‐
plasia	and	8.8%	for	cancer).3	 It	cannot	be	excluded	that	 the	 lower	
risk	of	atypical	hyperplasia	may	also	depend	on	changes	in	the	WHO	
classification.	Anyway,	the	risk	of	coexistent	cancer	is	by	far	lower	
than	that	observed	in	atypical	hyperplasia,	which	is	usually	treated	
conservatively	in	fertile	women.17	These	findings	support	the	feasi‐
bility	of	the	conservative	treatment	in	fertile	women.
To	date,	there	 is	no	standard	management	of	APA.	There	 is	no	
consensus	 about	 the	optimal	 treatment	 (conservative	or	 non‐con‐
servative;	 type	 of	 conservative	 treatment)	 or	 follow	 up	 (modality	
and	timing).
Based	on	the	risk	of	recurrence	(29.8%)	and	progression	(10.8%)	
even	after	TCR,	hysterectomy	might	be	advisable	as	a	 first	choice	
treatment.	However,	such	management	does	not	appear	suitable	for	
patients	desiring	pregnancy.
Considering	that	most	patients	were	premenopausal	(85.9%)	and	
nulliparous	(62.9%),	a	fertility‐sparing	treatment	appears	necessary.	
Several	 conservative	 approaches	were	 described	 in	 the	 literature,	
but	it	is	unclear	which	one	should	be	preferred.
In	 our	 study,	 initial	 response,	 final	 complete	 response	 and	 preg‐
nancy	rates	were	used	to	estimate	the	effectiveness	of	the	conservative	
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treatments,	and	progression	and	recurrence	rates	were	used	to	define	
the	safety.
According	 to	 our	 results,	 TCR	 (not	 followed	 by	 HT)	 appeared	
to	be	better	than	any	other	conservative	treatments	of	APA.	At	an	
overall	evaluation,	TCR	alone	appeared	an	effective	and	safe	fertil‐
ity‐sparing	treatment,	showing	initial	response	in	98.7%	of	treated	
patients,	 progression	 in	 10.8%,	 final	 complete	 response	 in	 77.3%,	
recurrence	in	29.8%	and	pregnancy	in	21.1%.
Remarkably,	TCR	showed	significantly	higher	rates	of	 initial	re‐
sponse	 than	 TCR+HT	 (98.7%	 vs	 69.2%);	 no	 significant	 differences	
were	found	with	respect	to	the	other	outcomes.	In	future	studies,	it	
would	be	interesting	to	assess	whether	the	responsiveness	of	APA	
to	progestins	may	be	influenced	by	expression	of	certain	molecules,	
as	observed	in	endometrial	hyperplasia	and	cancer.18,19
A	possible	advantage	of	TCR	without	HT	over	TCR+HT	may	be	
the	shorter	duration	of	the	treatment,	which	allows	attempts	to	con‐
ceive being starting earlier.
Based	on	our	results	and	the	adjunctive	costs	arising	from	the	ad‐
dition	of	HT	to	TCR,	there	seem	to	be	limited	evidence	to	recommend	
the	addition	of	HT	to	TCR	in	the	conservative	treatment	of	APA.
However,	the	TCR	techniques	adopted	differed	among	the	included	
studies	and	showed	different	results.	In	our	analysis,	the	best	results	
TA B L E  1  Patient	characteristics
Study (Ref) Country Design Sample size Study period
Patient 
selection
Patients
Age years, mean 
(range)
BMI kg/m2,  
mean (range)
Premenopausal, 
n (%)
Cycle irregular‐
ity, n (%)
Nulliparity, n 
(%)
Infertility, 
n (%) Symptoms (%) Other pathologies (%)
Nomura	
et al9
Japan Retrospective 18 2001‐2011 Consecutive 33.6	(26‐45) 21.9	(18.3‐27.6) 18	(100) 7	(38.8) 18	(100) ‐ ‐ ‐
Ma	et	al14 China Retrospective 43 2012‐2016 Consecutive 56	(17‐71) ‐ 22	(48.8) ‐ 5	(11.6) 3	(7.0%) 36	menorrhagia;	4	secondary	
anemia;	3	asymptomatic
8	diabetes	mellitus;	13	hypertension;	
1	hyperthyroidism;	9	uterine	
leiomyomas;	7	uterine	glandular	
myopathy;	4	history	of	endometrial	
polyps;	1	history	of	breast	cancer
Chiyoda	
et al7
Japan Retrospective 35 2003‐2015 Consecutive 35	(23‐43) 20.8	(16.6‐28.7) ‐ 11	(31.4) 35	(100) 1	(2.9) 24	hypermenorrhea;	5	
metrorrhagia;	1	amenorrhea;	1	
asymptomatic;	1	unknown
‐
Chen	et	al13 China Retrospective 10 2004‐2016 Consecutive 30	(23‐40) ‐ ‐ ‐ 7	(70) 9	(90) 2	hypermenorrhea;	2	metror‐
rhagia;	2	pelvic	mass;	1	
irregular uterine bleeding; 1 
menostaxis;	1	secondary	
infertility;	1	vaginal	bleeding
2 ovarian cysts; 1 uterine adenomy‐
oma; 1 uterine leiomyomas; 1 
hypertension;	1	diabetes;	1	
polycystic	ovarian	syndrome;	1	tubal	
pregnancy;	1	multiple	endometrial	
polyps
Grimbizis	
et al12
Greece Retrospective 9 1998‐2016 Consecutive 37.9	(29.6‐46.2) ‐ 8	(88.9) ‐ 1.0	±	1.1child 2	(22.2) 5 abnormal uterine bleeding; 2 
none
‐
Nomura	
et al8
Japan Retrospective 18 2001‐2011 Consecutive 33.6	(26‐45) 21.9	(18.3‐27.6) 18	(100) 7	(38.8) 18	(100) 3	(16.7) 10 abnormal uterine bleeding; 1 
vaginal	discharge;	1	
dysmenorrhea
‐
Matsumoto	
et al11
Japan Retrospective 29 1985‐2005 Consecutive 38	(22‐58) 23.2	±	6.2	SD 27	(93.1) 11	(37.9) 22	(75.9) 6	(35.3) 8	hypermenorrhea;	8	
dysmenorrhea
1	hypertension;	4	history	of	ovarian	
tumor;	6	anemia
Longacre	
et al6
USA Retrospective 55 ‐ Consecutive 39.9	(25‐73) 31 obese  
patients	(56.4)
53	(96) ‐ 28	(51) 15	(27.3) most common: abnormal uterine 
bleeding less common: vaginal 
discharge,	pelvic	pain,	
postcoital	spotting
1	history	of	breast	cancer;	1	
sclerocystic ovaries; 2 endometriosis; 
1 ovarian serous cystadenoma; 1 
diabetes	mellitus;	1	acromegaly;	7	
uterine leiomyomas
Fukunaga	
et al10
Japan Retrospective 6 1991‐1994 Consecutive 33	(22‐48) ‐ 6	(100) ‐ 6	(100) ‐ 6	abnormal	uterine	bleeding 1	history	of	uterine	tuberculosis;	1	
uterine leiomyomas
Young et al5 USA Retrospective 27 ‐ Consecutive 39.7	(21‐53) ‐ 26	(96.3) ‐ 10	(37) 3	(11.1) 24 abnormal uterine bleeding; 1 
vaginal	discharge;	1	
asymptomatic
2	Turner's	syndrome;	1	endometriosis
Mazur1 USA Retrospective 5 ‐ Consecutive 38	(33‐44) ‐ 5	(100) ‐ 3	(60) ‐ 5 abnormal uterine bleeding 2	hypertension;	2	diabetes;	1	uterine	
leiomyomas
Total 237 ‐	(17‐73) ‐	(16.6‐28.7) 165/192	(85.9) 29/82	(35.4) 134/213 
(62.9)
42/226	
(18.6)
51/182	(28)	abnormal	uterine	
bleeding;	36/182	(19.8)	
menorrhagia	34/182	(18.7)	
hypermenorrhea
19/175	(10.9)	uterine	leiomyomas	
13/175	(7.4)	hypertension	12/175	
(6.9)	diabetes	mellitus
‐,	not	reported.
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were	found	in	the	study	of	Ma	et	al.14	In	that	study,	the	TCR	technique	
was	performed	in	4	steps	according	to	Di	Spiezio	Sardo	et	al20,21: re‐
section	of	APA	(step	1);	removal	of	3‐4	mm	of	endometrium	adjacent	
to	the	 lesion	(step	2);	removal	of	2‐3	mm	of	myometrium	underlying	
the	lesion	(step	3);	multiple	random	endometrial	biopsies	(step	4).	Such	
a	technique	may	also	have	the	advantage	of	exploring	the	remaining	
endometrium	with	the	random	biopsies	better,	in	order	to	exclude	the	
presence	of	coexistent	atypical	hyperplasia	and	cancer.	These	condi‐
tions	should	indeed	have	priority	in	directing	the	management.	Thus,	
based	on	the	available	evidence,	TCR	technique	in	4	steps	might	be	the	
optimal	fertility‐sparing	treatment	for	women	with	APA.
It	would	be	 interesting	 to	 assess	whether	 rates	of	progression	
and	recurrence	may	be	affected	by	pregnancy.	Among	patients	who	
achieved	pregnancy,	only	1	case	of	recurrence	and	1	of	persistent	
disease	were	reported.6,13	These	findings	seem	to	be	in	accordance	
with	other	studies	that	advocated	a	protective	role	of	pregnancy	on	
APA.	 In	 fact,	Nomura	et	al8	 reported	 a	 significant	 inverse	 correla‐
tion	between	pregnancy	and	hysterectomy	on	multivariate	analysis.8 
However,	there	are	too	few	data	to	draw	conclusions.	We	hope	fur‐
ther	studies	will	help	in	investigating	this	aspect.
Great	uncertainty	exists	even	regarding	the	follow	up	of	patients	
diagnosed	with	APA.	 In	 fact,	 both	modality	 and	 timing	of	 follow	up	
TA B L E  1  Patient	characteristics
Study (Ref) Country Design Sample size Study period
Patient 
selection
Patients
Age years, mean 
(range)
BMI kg/m2,  
mean (range)
Premenopausal, 
n (%)
Cycle irregular‐
ity, n (%)
Nulliparity, n 
(%)
Infertility, 
n (%) Symptoms (%) Other pathologies (%)
Nomura	
et al9
Japan Retrospective 18 2001‐2011 Consecutive 33.6	(26‐45) 21.9	(18.3‐27.6) 18	(100) 7	(38.8) 18	(100) ‐ ‐ ‐
Ma	et	al14 China Retrospective 43 2012‐2016 Consecutive 56	(17‐71) ‐ 22	(48.8) ‐ 5	(11.6) 3	(7.0%) 36	menorrhagia;	4	secondary	
anemia;	3	asymptomatic
8	diabetes	mellitus;	13	hypertension;	
1	hyperthyroidism;	9	uterine	
leiomyomas;	7	uterine	glandular	
myopathy;	4	history	of	endometrial	
polyps;	1	history	of	breast	cancer
Chiyoda	
et al7
Japan Retrospective 35 2003‐2015 Consecutive 35	(23‐43) 20.8	(16.6‐28.7) ‐ 11	(31.4) 35	(100) 1	(2.9) 24	hypermenorrhea;	5	
metrorrhagia;	1	amenorrhea;	1	
asymptomatic;	1	unknown
‐
Chen	et	al13 China Retrospective 10 2004‐2016 Consecutive 30	(23‐40) ‐ ‐ ‐ 7	(70) 9	(90) 2	hypermenorrhea;	2	metror‐
rhagia;	2	pelvic	mass;	1	
irregular uterine bleeding; 1 
menostaxis;	1	secondary	
infertility;	1	vaginal	bleeding
2 ovarian cysts; 1 uterine adenomy‐
oma; 1 uterine leiomyomas; 1 
hypertension;	1	diabetes;	1	
polycystic	ovarian	syndrome;	1	tubal	
pregnancy;	1	multiple	endometrial	
polyps
Grimbizis	
et al12
Greece Retrospective 9 1998‐2016 Consecutive 37.9	(29.6‐46.2) ‐ 8	(88.9) ‐ 1.0	±	1.1child 2	(22.2) 5 abnormal uterine bleeding; 2 
none
‐
Nomura	
et al8
Japan Retrospective 18 2001‐2011 Consecutive 33.6	(26‐45) 21.9	(18.3‐27.6) 18	(100) 7	(38.8) 18	(100) 3	(16.7) 10 abnormal uterine bleeding; 1 
vaginal	discharge;	1	
dysmenorrhea
‐
Matsumoto	
et al11
Japan Retrospective 29 1985‐2005 Consecutive 38	(22‐58) 23.2	±	6.2	SD 27	(93.1) 11	(37.9) 22	(75.9) 6	(35.3) 8	hypermenorrhea;	8	
dysmenorrhea
1	hypertension;	4	history	of	ovarian	
tumor;	6	anemia
Longacre	
et al6
USA Retrospective 55 ‐ Consecutive 39.9	(25‐73) 31 obese  
patients	(56.4)
53	(96) ‐ 28	(51) 15	(27.3) most common: abnormal uterine 
bleeding less common: vaginal 
discharge,	pelvic	pain,	
postcoital	spotting
1	history	of	breast	cancer;	1	
sclerocystic ovaries; 2 endometriosis; 
1 ovarian serous cystadenoma; 1 
diabetes	mellitus;	1	acromegaly;	7	
uterine leiomyomas
Fukunaga	
et al10
Japan Retrospective 6 1991‐1994 Consecutive 33	(22‐48) ‐ 6	(100) ‐ 6	(100) ‐ 6	abnormal	uterine	bleeding 1	history	of	uterine	tuberculosis;	1	
uterine leiomyomas
Young et al5 USA Retrospective 27 ‐ Consecutive 39.7	(21‐53) ‐ 26	(96.3) ‐ 10	(37) 3	(11.1) 24 abnormal uterine bleeding; 1 
vaginal	discharge;	1	
asymptomatic
2	Turner's	syndrome;	1	endometriosis
Mazur1 USA Retrospective 5 ‐ Consecutive 38	(33‐44) ‐ 5	(100) ‐ 3	(60) ‐ 5 abnormal uterine bleeding 2	hypertension;	2	diabetes;	1	uterine	
leiomyomas
Total 237 ‐	(17‐73) ‐	(16.6‐28.7) 165/192	(85.9) 29/82	(35.4) 134/213 
(62.9)
42/226	
(18.6)
51/182	(28)	abnormal	uterine	
bleeding;	36/182	(19.8)	
menorrhagia	34/182	(18.7)	
hypermenorrhea
19/175	(10.9)	uterine	leiomyomas	
13/175	(7.4)	hypertension	12/175	
(6.9)	diabetes	mellitus
‐,	not	reported.
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were	different	among	the	studies.	In	three	studies,8,9,13	D&C	or	hys‐
teroscopic	 specimens	 were	 obtained	 only	 in	 the	 case	 of	 suspicious	
findings	on	ultrasonography,	whereas	 in	the	other	studies,	histologi‐
cal	examination	was	performed	at	every	follow‐up	visit.	Given	the	risk	
of	recurrence,	progression	and	coexistent	atypical	hyperplasia	and/or	
cancer,	we	think	that	a	close	follow	up	based	on	histological	examina‐
tion would be advisable.
The	interval	between	follow‐up	visits	ranged	from	3	months	to	
1	year.	 It	 should	be	noted	 that	up	 to	 four	 recurrences,	with	 a	dis‐
ease‐free	 interval	up	 to	60	months,	were	described,	and	1	patient	
needed	to	undergo	hysterectomy	84	months	after	the	beginning	of	
the	 conservative	 treatment.	 Therefore,	 a	 long	 follow‐up	 duration	
should	be	advisable.	The	follow‐up	modality	described	by	Nomura	
et	al	appears	to	be	a	safe	approach,8,9	consisting	of	dilation	and	cu‐
rettage	or	 hysteroscopic	 biopsy	plus	 transvaginal	 ultrasonography	
every	3	months	for	the	first	2	years,	every	4‐6	months	for	another	
3	years,	and	once	a	year	thereafter.8,9
In	one	 study,	 tumor	markers	CA125	and	CA19.9	were	also	as‐
sessed,	 reporting	 normal	 values7;	 however,	 evidence	 for	 their	 use	
is	lacking.	Instead,	it	is	possible	that	some	markers	associated	with	
TA B L E  5  Reproductive	outcomes	of	fertility‐sparing	treatment
Study (Ref) Treatment
Pregnancies
Total (%) Details
Nomura	et	al9 HT 2/5M	(40)	2/13	(15.4) ‐
Ma	et	al14 TCR ‐ ‐
Chiyoda	et	al7 TCR 6/35	(17.1) 1	patient	conceived	after	a	first	recurrence	treated	by	
TCR	and	1	after	a	third	recurrence	treated	by	a	fourth	
TCR	4	patients	had	normal	vaginal	delivery	and	1	
cesarean	delivery	owing	to	a	fetal	condition	Details	
about	1	women	were	not	reported	because	pregnancy	
occurred	at	the	last	follow	up
Chen	et	al13 TCR+HT 7/10	(70) 1	patient	conceived	2	times:	1	natural	delivery	and	1	twin	
pregnancy	with	cesarean	section;	3	patients	had	term	
delivery	with	natural	conception	5	patients	underwent	
in	vitro	fertilization	and	embryo	transfer	(IVF‐ET):	2	
failed,	while	3	had	a	cesarean	delivery	at	21,	37	and	
50	mo	2	of	3	non‐pregnant	patients	were	relatively	
older,	and	another	was	a	recent	case
Grimbizis	et	al12 TCR 2/3	(66.6) 3	patients	stated	that	they	did	not	completed	their	family:	
1	patient	had	a	delivery	6	y	after	the	initial	diagnosis,	1	
had	a	delivery	1	y	after	the	initial	diagnosis	by	intrauter‐
ine	insemination,	and	1	was	under	consideration	for	
using	assisted	reproduction	techniques
Nomura	et	al8 HT 4/18	(22.2) 5	patients	tried	to	conceive:	3	conceived	spontaneously	
and	1	conceived	2	times	(the	first	one	with	clomiphene	
and	the	second	one	spontaneously)
Matsumoto	et	al11 D&C	Vaginal	
resection	TCR
‐ ‐
Longacre	et	al6 TCR+HT 5/29	(17.2) 5	patients	with	recurrent	or	persistent	lesions	subse‐
quently	became	pregnant	and	delivered	normal	full‐term	
infants,	including	one	patient	who	bore	two	children
Fukunaga	et	al10 D&C+HT	TCR ‐ ‐
Young et al5 D&C	TCR ‐ ‐
Mazur1 D&C 1/5	(20) ‐
Total All	treatment 24/95	(25.3) ‐
HT 2/5M	(40)	2/13	(15.4)
TCR 8/38	(21.1)
TCR+HT 12/39	(30.8)
D&C ‐
D&C+HT ‐
CR,	complete	response;	D&C,	dilation	and	curettage;	HBSO,	hysterectomy	and	bilateral	salpingo‐oophorectomy;	HT,	hormonal	therapy;	Hy,	hysterec‐
tomy;	M,	MPA	maintenance;	P,	persistence;	PR,	partial	response;	R,	recurrence;	TCR,	hysteroscopic	transcervical	resection;	‐,	not	reported.
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premalignant	endometrial	hyperplasia	or	endometrial	cancer	might	
also	be	useful	in	the	diagnosis	and	risk	stratification	of	APA,	as	these	
two	lesions	share	several	molecular	features.22‐26
To	the	best	of	our	knowledge,	this	study	is	the	first	quantitative	
systematic	review	about	APA.	We	aimed	to	determine	the	optimal	
treatment	and	follow	up	for	this	 lesion,	which	is	still	not	standard‐
ized.	Moreover,	we	tried	to	 improve	the	quality	of	evidence	about	
clinicopathologic	characteristics	and	behavior	of	APA,	as	well	as	the	
risks	of	cancer	and	recurrence.
Limitations	 to	our	 results	might	be	 the	 retrospective	design	of	
the	included	studies,	the	relatively	small	sample	size	and	the	lack	of	
studies	that	compares	different	treatments.	Such	limitations	partic‐
ularly	 affect	 comparisons	 among	TCR	 techniques.	However,	 given	
the	rarity	of	APA,	prospective	large	studies	are	difficult	to	perform.	
To	date,	evidence	driving	the	management	of	APA	has	been	based	on	
case	reports	and	small	retrospective	case	series.
Our	systematic	review	with	non‐weighted	quantitative	synthesis	
of	the	data	may	provide	the	first	statistical	evidence	in	this	field,	and	
may	represent	a	step	towards	an	evidence‐based	standardization	of	
the	management	of	APA.
5  | CONCLUSION
Given	 the	 risk	 of	 recurrence	 and	 progression,	 APA	 might	 be	
treated	by	hysterectomy	in	patients	with	no	desire	for	pregnancy.	
Since	most	patients	 are	premenopausal,	 a	 fertility‐sparing	 treat‐
ment	 is	necessary.	TCR	may	be	considered	the	first‐line	fertility‐
sparing	treatment,	as	it	showed	superiority	all	other	conservative	
approaches	in	terms	of	both	effectiveness	and	safety.	In	particular,	
the	4‐step	TCR	described	by	Di	Spiezio	Sardo	et	al14,17	showed	the	
best	results.	The	follow	up	might	be	based	on	transvaginal	ultra‐
sonography	and	histological	examination	every	3	months	 for	 the	
first	 2	years,	 every	 4‐6	months	 for	 another	 3	years,	 and	 once	 a	
year	thereafter.
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